News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 361–396
- Matches
- 2542
- Sources here
- 22
- Companies here
- 27
Active search
2542 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside
Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …
What's Going On With Lam Research Stock Thursday?
Lam Research stock traded mostly flat on Thursday, consolidating after a strong 12-month run, with investors watching key technical support levels. The company is also expanding its semiconductor workforce development initiatives and its operations in Singapore. Despite a premium valuation and mixed near-term technical …
Arch Insurance Intl. appoints James Mecham as Deputy CUO for Long Tail Lines
Arch Insurance International has appointed James Mecham as Deputy Chief Underwriting Officer (CUO) for Long Tail Lines, effective immediately. Mecham will support the underwriting strategy for long tail portfolios across various business units and will also serve as Head of General Casualty. This appointment …
Lam Research Plans To Invest Over $3 Bln To Expand Research, Development Lab Network In AI Era
(RTTNews) - Lam Research Corporation (LRCX), a semiconductor manufacturing equipment and services provider, said that it intends to invest more than $3 billion over the next five years to expand its global research and development lab network. This investment will increase the company's experiment …
Sharemaestro market context Trend signal active 52 weeks +205.7%Arcos Dorados Holdings Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ARCO) 2026-08-14
This article first appeared on GuruFocus. Total Revenue: Reached $1.3 billion, the highest ever quarterly revenue, up more than 14% versus the prior year quarter. System-wide Comparable Sales: Grew 15.3%, driven by a higher average check and the best guest volume performance of the …
Why Lam Research (LRCX) Is Up 10.2% After $3 Billion Global R&D Lab Expansion Plan
In August 2026, Lam Research announced plans to invest more than US$3.00 billion over five years to expand its global R&D lab network, aiming to lift experiment capacity by over 50% and compress product development cycles for semiconductor customers across the US, Asia, and …
Sharemaestro market context Trend signal active 52 weeks +205.7%Barclays PLC (TAVI) discloses 15,654-share stake in Tavia Acquisition Corp
Barclays PLC has disclosed a beneficial ownership of 15,654 shares in Tavia Acquisition Corp (TAVI), representing 0.17% of the common stock. This filing, a SCHEDULE 13G/A, indicates that Barclays PLC holds sole voting and dispositive power over these shares, categorizing the stake as less …
Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …
Marcus & Millichap arranges $3.9 million sale of 56,000 s/f 470 Pine St.
Marcus & Millichap successfully brokered the sale of 470 Pine St., a 56,000 square foot multi-tenant building in downtown Manchester, NH, for $3.9 million. The property, originally built in 1924 and converted from a mill to a school, is fully occupied by three educational …
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …
Digimarc outlines go-to-market rebuild as Secure Gift Card pipeline grows over 30x to more than 31 retailers
Earnings Call Insights: Digimarc (DMRC) Q2 2026 MANAGEMENT VIEW * CEO Paul Carreiro framed the quarter around execution changes, saying Digimarc is “held back by commercial execution gap that is entirely fixable” and that “what was missing was leadership focus, structure and accountability to …
Barclays PLC (NHIC) trims Newhold Investment Corp II-A stake to 4.13% of shares
Barclays PLC has reported a reduction in its beneficial ownership of Newhold Investment Corp II-A common stock, now holding 4.13% of the class. This amounts to 863,817 shares, with the majority having sole voting and dispositive power. The filing indicates that Barclays' stake is …
Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc
Barclays PLC has reported a beneficial ownership of 2,342,118 shares of Penumbra Inc (PEN) common stock, representing 5.95% of the class as of June 30, 2026. The filing, a Schedule 13G, indicates that Barclays holds sole voting and dispositive power over 2,340,999 shares and …
Barclays PLC discloses 1.23M Axiom Intelligence (AXIN) shares on Schedule 13G
Barclays PLC has reported a beneficial ownership of 1,231,531 shares of Axiom Intelligence (AXIN) Class A common stock, representing a 5.97% stake. The filing indicates Barclays PLC has sole voting and dispositive power over 1,201,531 shares, and shared power over an additional 30,000 shares. …
Digimarc Reports Second Quarter 2026 Financial Results
Digimarc Corporation reported its second-quarter 2026 financial results, with total revenue decreasing to $7.4 million from $8.0 million in Q2 2025, primarily due to lower subscription revenue following contract expirations. Despite a net loss increase to $12.1 million, the company's CEO, Paul Carreiro, expressed …
Here’s How Much You Would Have Made Owning ACM Research Stock In The Last 5 Years
ACM Research (NASDAQ: ACMR) has outperformed the market over the last five years, with an annualized return of 24.64%. An initial investment of $1000 in ACMR stock five years ago would now be worth $2,921.90. This demonstrates the significant impact of compounded returns on …
Barclays PLC (FWRD) discloses 7.84% stake in Forward Air on Schedule 13G
Barclays PLC has disclosed a 7.84% beneficial ownership stake in Forward Air Corp (FWRD) through a Schedule 13G filing. This represents 2,480,010 shares, with Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd identified as involved subsidiaries. The filing indicates that Barclays …
Earnings call transcript: Digimarc beats Q2 2026 estimates but shares fall
Digimarc (DMRC) reported a narrower-than-expected loss and slightly better revenue for Q2 2026, beating analyst estimates. However, shares fell due to ongoing pressure on recurring revenue from contract losses and delayed significant growth in its gift-card business until late 2026 and early 2027. The …
Archimedes Tech SPAC Partners II Reports Q2 2026 10-Q with Significant PIPE-Related Losses
Archimedes Tech SPAC Partners II reported a significant net loss of $135,048,119 for the first half of 2026, primarily due to a $100,000,000 PIPE subscription expense and a $37,942,000 adjustment in the fair value of a PIPE subscription derivative liability. This contrasts sharply with …
FactSet Research Systems Inc. Announces Quarterly Dividend of $1.16 (NYSE:FDS)
FactSet Research Systems Inc. (NYSE:FDS) has announced a quarterly dividend of $1.16 per share, maintaining its 27-year streak of dividend increases. The dividend will be paid on September 17th to shareholders of record on August 31st, representing an annualized dividend of $4.64 and a …